The Russian Direct Investment Fund (RDIF) and pharmaceutical company Hetero have agreed to produce 100 million doses of Sputnik V vaccine in India every year. Russia’s Sovereign Wealth Fund gave this information in a statement.
The statement said Sputnik V, a potential vaccine for the corona virus, is intended to begin production in 2021. The third phase of this vaccine is currently being tested in Belarus, UAE, Venezuela and other countries. The RDIF said that Phase II and Phase III trials are underway in India. Domestic pharmaceutical company Dr Reddy’s Laboratories and RDIF have received the second and third stage trials of Sputnik V vaccine in India from the Drug Controller General of India (DCGI).
More than 50 countries have requested more than 1.2 billion doses of the Sputnik V vaccine. RDIF said the vaccine for the global market would be produced by RDIF partners in India, Brazil, China, South Korea and other countries.
Kirill Dimitrig, CEO of the Russian company RDIF, said, “We are pleased to announce the agreement between RDIF and Hetero that this will pave the way for the production of safe and highly effective Sputnik V vaccine in India.”
The RDIF claimed on Tuesday that the Sputnik V Covid-19 vaccine had an impact of over 95 percent and that a single dose would cost less than US $ 10 (about Rs 740) for international markets. B Murali Krishna Reddy, International Marketing Director, Hetero Labs, said the company is happy to be the production partner of Sputnik V vaccine and is awaiting test results.